Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC011 in Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma
NCT07473167Phase 2Recruiting
- Sponsor
- TiCARos Therapeutics
- Start
- Aug 2023
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in diffuse large B-cell lymphoma (DLBCL), sponsored by TiCARos Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 4 weeks, Maximum Tolerated Dose at 4 weeks and 8 more. Started Aug 2023; status: recruiting.
02
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07473167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473167.